IN8bio, Inc. (NASDAQ:INAB) CEO William Tai-Wei Ho Buys 23,800 Shares

IN8bio, Inc. (NASDAQ:INAB) CEO William Tai-Wei Ho purchased 23,800 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average price of $1.05 per share, for a total transaction of $24,990.00. Following the acquisition, the chief executive officer now owns 2,339,545 shares in the company, valued at approximately $2,456,522.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

IN8bio Price Performance

Shares of NASDAQ INAB opened at $1.09 on Tuesday. The stock has a market capitalization of $34.44 million, a price-to-earnings ratio of -0.89 and a beta of -0.22. IN8bio, Inc. has a 12 month low of $0.98 and a 12 month high of $3.95. The firm’s 50 day simple moving average is $1.44 and its 200-day simple moving average is $1.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.15 and a quick ratio of 5.15.

Institutional Investors Weigh In On IN8bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new stake in shares of IN8bio during the 4th quarter worth approximately $26,000. Renaissance Technologies LLC acquired a new stake in shares of IN8bio during the 2nd quarter worth approximately $33,000. Overbrook Management Corp acquired a new stake in shares of IN8bio during the 2nd quarter worth approximately $52,000. BlackRock Inc. grew its stake in shares of IN8bio by 70.8% during the 1st quarter. BlackRock Inc. now owns 16,334 shares of the company’s stock worth $54,000 after purchasing an additional 6,773 shares during the period. Finally, Northern Trust Corp grew its stake in shares of IN8bio by 226.4% during the 2nd quarter. Northern Trust Corp now owns 43,258 shares of the company’s stock worth $67,000 after purchasing an additional 30,005 shares during the period. Institutional investors and hedge funds own 7.37% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of IN8bio in a report on Friday, August 11th.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.